SHARE

Pazoo Inc (OTCMKTS:PZOO) reported that last month its subsidiary received notice of acceptance from the State of Nevada. The notice states that the lab has met all of the requirements to perform operations as a medical marijuana testing lab in the State of Nevada.

The highlights

Pazoo subsidiary’s lab has passed all stringent State checks, and with this approval the Certificate is being sent to the lab. The last obstacle to opening the laboratory is obtaining the license from City of Las Vegas, the request for which is still pending.

Moreover, as the company expands its industry leadership and interstate operations, it is proud to report that CEO, David Cunic, has joined the advisory board of the MMCM. It a Maine Trade Association established to the promotion and support of safe access to medical pot. MMCM has been offering advocacy and education for caregivers and patients in Maine since 2010.

New updates

Pazoo reported that its subsidiary MA & Associates lab in Las Vegas continues to advance with new validating process for sample tests in order to meet the strict cannabis lab testing guidelines set by the state of Nevada. It will ensure that each sample is assessed and carefully examined. The new validating process will significantly minimize the processing period for microbial tests by up to 65% on all cannabis samples examined at MA & Associates lab.

Trisha Scott of MA and Associates stated that as a part of leading process, there is a need to use new validating process to better serve the medical community. Scott is also a leading industry supporter for woman executives in the emerging cannabis industry.

Cunic said that they are proud of MA & Associates and Scott’s commitment to excellence as they finish getting set for the cannabis lab to open. They are delighted that the Pazoo’s set excellence standards are being employed for cannabis lab which allows them to look at each sample from a critical lens.

Lotus Bio-Technology Development Corp (OTCMKTS:LBTD) Closing In On A New 52-Week High

Lotus Bio-Technology Development Corp (OTCMKTS:LBTD) could post a new 52-week high in the market thanks to an impressive run backed by a wave of positive news. With the stock now trading at highs of $0.55 a share, topping the 52-week high of $0.59 is in play given improved investor’s sentiments.

A string of strategic collaborations have helped bolster the company’s prospects given the growth opportunities that have come into play with the exponential growth in China’s organic food market. With the strategic alliances, the company is planning to come up with more sustainable organic products as it looks to service the ever-growing demand.

Teaming up with other biological and medical distributors is also part of an effort that seeks to make the Lotus Bio-Technology Development Corp (OTCMKTS:LBTD)’s products available to a wider market. With the likes of Hunan Cangshi Biotechnology Company onboard, the company hopes to pursue new opportunities on the international scene as well.

LEAVE A REPLY